Cargando…
SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
Malignant melanoma is the most aggressive skin cancer and can only be cured if detected early. Unfortunately, later stages of the disease do not guarantee success due to the rapid rate of melanoma cell metastasis and their high resistance to applied therapies. The search for new molecular targets an...
Autores principales: | Karwaciak, Iwona, Sałkowska, Anna, Karaś, Kaja, Sobalska-Kwapis, Marta, Walczak-Drzewiecka, Aurelia, Pułaski, Łukasz, Strapagiel, Dominik, Dastych, Jarosław, Ratajewski, Marcin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562913/ https://www.ncbi.nlm.nih.gov/pubmed/31091806 http://dx.doi.org/10.3390/cancers11050673 |
Ejemplares similares
-
Identification of Novel Molecular Markers of Human Th17 Cells
por: Sałkowska, Anna, et al.
Publicado: (2020) -
Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019) -
Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism
por: Karwaciak, Iwona, et al.
Publicado: (2021) -
The Dichotomous Nature of AZ5104 (an EGFR Inhibitor) Towards RORγ and RORγT
por: Karaś, Kaja, et al.
Publicado: (2019) -
Functional Analysis of the rs774872314, rs116171003, rs200231898 and rs201107751 Polymorphisms in the Human RORγT Gene Promoter Region
por: Ratajewski, Marcin, et al.
Publicado: (2017)